Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
Springworks Therapeutics Inc. (SWTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,460,756 | $125,037,114 | -10% | 4.66% |
| 2. | Boxer Capital Aaron Davis And Christopher Fuglesang | 3,421,541 | $123,620,276 | 10.52% | |
| 3. | Maverick Capital Lee Ainslie | 2,891,852 | $104,482,613 | +5% | 1.88% |
| 4. | EcoR1 Capital Oleg Nodelman | 1,560,000 | $56,362,800 | 2.13% | |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,500,000 | $54,195,000 | 0.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 50,000 | Large Shareholder, Director | 4,593,847 | 2019-09-17 | Filing | |
| $18.00 | 275,000 | Large Shareholder, Director | 7,406,307 | 2019-09-17 | Filing | |
| $18.00 | 275,000 | Large Shareholder | 7,406,307 | 2019-09-17 | Filing | |
| $18.00 | 150,000 | Large Shareholder | 7,281,307 | 2019-09-17 | Filing | |
| $18.00 | 50,000 | Large Shareholder | 4,593,847 | 2019-09-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $56.20 | 400 | Officer | 169,712 | 2025-03-03 | Filing | |
| $55.12 | 3,598 | Officer | 170,112 | 2025-03-03 | Filing | |
| $54.26 | 12,078 | Officer | 173,710 | 2025-03-03 | Filing | |
| $53.12 | 3,924 | Officer | 185,788 | 2025-03-03 | Filing | |
| $56.89 | 600 | Officer, Director | 954,869 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,157,960 | $403,137,095 | 0.02% | |
| 2. | 7,158,871 | $258,650,009 | 0% | |
| 3. | 5,960,359 | $215,347,771 | 0% | |
| 4. | 3,000,986 | $108,425,624 | 0% | |
| 5. | 2,391,412 | $86,401,716 | 0.09% |
News See All
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Tanya, and I will be your conference operator today.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q2 2024 Earnings Call Transcript
Operator: Good morning. My name is Gigi, and I'll be your conference operator today. I would like to welcome everyone to the SpringWorks Therapeutics Second Quarter 2024 Earnings Conference Call.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript
Operator: Good morning. My name is Tawanda, and I will be your conference operator today.
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.